Search Results - "partitioned survival model"
-
1
Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer
Published 2025-07-01Subjects: Get full textObjectiveBased on findings from the GEMSTONE-303 trial, the sugemalimab plus capecitabine and oxaliplatin regimen showed superior clinical efficacy compared to chemotherapy alone in advanced gastric cancer patients. This economic evaluation study assesses the cost-effectiveness of sugemalimab combin...
Article -
2
Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
Published 2025-07-01Subjects: Get full textBackgroundThe COMPASSION-15 trial confirmed the safety and effectiveness of cadonilimab, a bispecific antibody targeting both programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4), in treating human epidermal growth factor receptor 2 (HER2) negative advanced gastric or gastroesopha...
Article -
3
Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis
Published 2025-07-01Subjects: Get full textObjectiveThe aim of this study was to evaluate the cost-effectiveness of toripalimab plus chemotherapy compared to chemotherapy alone as first-line therapy for extensive-stage small cell lung cancer(ES-SCLC) from the Chinese medical perspective.MethodsOur study utilized a partitioned survival model...
Article